Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ABH2 SPECT/CT
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This prospective study will investigate the potential usefulness of 99mTc-ABH2 SPECT/CT in the diagnostic performance and evaluation efficacy of breast cancer.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• clinically suspected primary breast cancer by mammography or ultrasonography and being able to sign the written informed consent form
Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
Yuwei Zhang
ywzhangwork@163.com
+8618511071577
Backup
Hongli MD Jing
Time Frame
Start Date: 2023-03-20
Estimated Completion Date: 2024-01-30
Participants
Target number of participants: 40
Treatments
Experimental: 99mTc-ABH2 SPECT/CT
The patients will be injected with 5.55 to 7.4 MBq per kilogram body weight of 99mTc-ABH2 in one dose intravenously and undergo SPECT/CT scan 1h to 2h later.
Related Therapeutic Areas
Sponsors
Leads: Peking Union Medical College Hospital